### RETRACTION

# Targeting of KDM5A by miR-421 in Human Ovarian Cancer Suppresses the Progression of Ovarian Cancer Cells [Retraction]

Ren F, Shrestha C, Shi H, et al. Onco Targets Ther. 2020;13;9419-9428.

At the authors request, we, the Editor and Publisher of the journal *OncoTargets and Therapy*, have retracted the following article.

Following publication of the article, concerns were raised about the duplication of images from another article authored by the first author, Fang Ren. Specifically,

- The image for Figure 4H, OVCAR-8, miR-421 mimics, has been duplicated with an image for Figure 4F, MDA-MB-231, anti-miR-374a, from Zhang J, He Y, Yu Y, et al. Upregulation of miR-374a promotes tumor metastasis and progression by downregulating LACTB and predicts unfavorable prognosis in breast cancer. *Cancer Med.* 2018;7:3351–3362. https://doi.org/10.1002/cam4.1576.
- In addition, images for Figure 5D, Lenti-NC group and Lenti-miR-421, Ki-67 have been duplicated.

The authors responded to our queries but were unable to provide a satisfactory explanation for the duplicated images or provide satisfactory data for the study. As verifying the validity of published work is core to the integrity of the scholarly record, the authors requested to retract the article and we, the editor and publisher, agreed with this decision.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

#### **OncoTargets and Therapy**

## Dovepress

359

### Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S474059

#### OncoTargets and Therapy 2024:17 359

© 2024 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).